Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report
Date:3/19/2012

cStyle" type="disc">
  • Quality Financing.  Secured a financing in March 2011 yielding gross proceeds of $15 million with fundamental health care investors at market terms and without warrant coverage.
  • BEMA Buprenorphine - Chronic Pain.  Completed and announced results of the Phase 3, randomized, placebo-controlled clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic low back pain in a mixed population of opioid naive and experienced patients.  While the primary endpoint, overall pain intensity difference between BEMA Buprenorphine and placebo, was not achieved, a near statistically significant difference between BEMA Buprenorphine and placebo was seen in the opioid experienced group of patients in the trial (p=0.067), and further, when eliminating the group of patients that did not titrate beyond the starting dose, a statistically significant difference between BEMA Buprenorphine and placebo (p=0.025) was identified.  The knowledge gained in the study is being directly applied in partnership with Endo to the design of two additional Phase 3 trials anticipated to start in the third quarter of 2012.  BDSI believes such knowledge will enhance the probability of such trials meeting their primary endpoints.
  • BNX - Opioid Dependence.  Obtained positive results from two studies assessing the pharmacokinetics of BNX.  Results of the studies demonstrated the ability of the BEMA formulation to meet the key pharmacokinetic goal of delivering plasma concentrations of buprenorphine in the range needed to treat opioid dependence while minimizing the exposure to the abuse deterrent, naloxone.  Results of the studies were shared with FDA and an agreement was reached on the development program for BNX that is anticipated to result in a New Drug Application (NDA) for the treatment of opioid dependence in the first half of 2013.  Key data results from the pivotal phar
    '/>"/>

  • SOURCE BioDelivery Sciences International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
    2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
    3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
    4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
    5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
    6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
    7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
    8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
    9. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
    10. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
    11. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... 30, 2014  Hologic, Inc. (NASDAQ: HOLX ... President and Chief Executive Officer, will preside over the ... the first day of Breast Cancer Awareness Month. In ... focused on the important benefits of Hologic,s 3D Mammography ... as clinically superior to traditional mammography. ...
    (Date:9/30/2014)... 30, 2014 This study provides an ... informatics solutions including nuclear imaging informatics, PET imaging ... study assesses the size of the market based ... and projects future growth based on the current ... taking place in the broader markets for imaging ...
    (Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
    Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
    ... OrthoWorx, the newly formed industry, community and education initiative to ... is working to connect the orthopedics capital of the world ... , In a September report, Warsaw, ... overview, analysis and blueprint for future industry and community growth, ...
    ... , , KNOXVILLE, Tenn., Dec. 15 Medical researchers ... their revolutionary new technology for a simple blood test to ... of its pre-clinical trials for the ColoMarker(TM) assay, EDP has ... of its use. Via an inexpensive blood test, ColoMarker(TM) ...
    Cached Medicine Technology:OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 2OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 3Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2
    (Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
    (Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
    (Date:10/1/2014)... 01, 2014 Scientists at the University ... that target immune system proteins has the power to ... posted details of the new study on their website. ... , Researchers in the UWA School of Pathology and ... to mice with mesothelioma with promising results. , ...
    (Date:10/1/2014)... October 01, 2014 October is national ... and early detection plans while raising money for breast ... Breast Cancer Awareness Month in the effort to ... to promote the importance of having access to clean, ... may be linked to certain forms of cancer. ...
    (Date:10/1/2014)... WA (PRWEB) October 01, 2014 Two ... will take them across the country in an effort ... today’s military families. The cyclists, a father-daughter team, ... states, beginning in Blaine, Washington and finishing in Key ... benefit Hope For The Warriors®, a national nonprofit organization ...
    Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
    ... may indicate more severe depression, rather than direct cause-and-effect, ... Women who use antidepressants appear to be at heightened ... of the link remains unclear, researchers say. , The ... the researchers said. , "We suspect that their ...
    ... of the U.S. Conference of Catholic Bishops, Committee on ... embryonic stem cell research "a sad victory of politics ... first time in U.S. history, federal tax dollars will ... embryos for stem cell research. Cardinal Rigali also cited ...
    ... MARCOS, Calif., March 9 Natural Alternatives International, Inc. ... formulator and manufacturer of customized nutritional supplements, and ... based distributor of raw materials to the sports ... industries, today jointly announced their licensing agreement of ...
    ... condensed format at 15 locations statewide and online to ... PARK, Pa., March 9 School nurses in Pennsylvania ... with Penn State,s Professional Development Program for ... new courses for the program, to include timely, relevant ...
    ... (Nasdaq: MDVN ) today announced that ... discuss fourth quarter and year-end 2008 financial results and provide ... 4:30 p.m. Eastern Time. A press release for the fourth ... after markets close on March 16, 2009. Interested parties may ...
    ... In Kentucky, nearly one out of every two of ... a quarter of the dentists accept the insurance; therefore ... it comes to seeing a dentist or receiving dental ... Healthcare, manufacturer of Aquafresh(R) and Sensodyne(R), has donated 10,000 ...
    Cached Medicine News:Health News:Antidepressant Use Tied to Cardiac Death in Women 2Health News:Antidepressant Use Tied to Cardiac Death in Women 3Health News:Executive Order on Embryonic Stem Cells 'A Sad Victory of Politics Over Science and Ethics,' Says Cardinal Rigali 2Health News:Natural Alternatives International, Inc. Announces Carnosyn(R) Beta-Alanine Licensing Agreement 2Health News:Natural Alternatives International, Inc. Announces Carnosyn(R) Beta-Alanine Licensing Agreement 3Health News:Natural Alternatives International, Inc. Announces Carnosyn(R) Beta-Alanine Licensing Agreement 4Health News:Penn State Expands Professional Development Program for School Nurses, Now in its Seventh Year 2Health News:Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009 2Health News:GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia 2
    ... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
    SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
    SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
    SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
    Medicine Products: